
Panfirst 40mg Injection
Marketer
Zyphar's Pharmaceuticals Pvt Ltd
Salt Composition
Pantoprazole (40mg)
Overview Panfirst 40mg Injection
Gastric acid production is reduced by the intravenous administration of Acidaze 40mg, a medication indicated for various gastrointestinal disorders. These include conditions like acid reflux, peptic ulcers, and Zollinger-Ellison syndrome, offering both symptomatic relief and healing support. Acidaze 40mg is also prophylactically administered to critically ill patients to prevent stress ulcers and pre-anesthesia to mitigate aspiration risks. Classified as a proton pump inhibitor (PPI), this injectable formulation is exclusively administered by medical professionals when deemed more appropriate than oral medication. Dosage is individualized, depending on patient response and condition severity, with treatment duration determined by your physician. Consistent adherence to the prescribed regimen is crucial, even with rapid symptom resolution. Dietary modifications, such as smaller, more frequent meals, and avoidance of caffeine, spicy, and fatty foods, can enhance treatment effectiveness. Common, typically mild, adverse effects may include nausea, vomiting, headache, dizziness, gas, diarrhea, abdominal discomfort, and thrombophlebitis. Persistent or bothersome symptoms warrant medical attention. Prolonged use, particularly exceeding one year, may elevate the risk of fractures, especially at higher doses. Discuss bone health preservation strategies, including calcium and vitamin D supplementation, with your doctor. Prior to Acidaze 40mg initiation, inform your physician of any severe liver impairment, HIV medication use, prior PPI allergies, or pre-existing osteoporosis. Pregnant or lactating individuals should seek medical counsel. Alcohol consumption should be avoided due to its potential to exacerbate symptoms. Refrain from operating machinery or driving if experiencing dizziness or drowsiness.
Uses of Panfirst 40mg Injection
Managing gastroesophageal reflux, peptic ulcers, and Zollinger-Ellison syndrome.
Major Benefits of Panfirst 40mg Injection:
This medication will be administered by your healthcare provider. Self-medication is strictly prohibited.
Common Side effects of Panfirst 40mg Injection:
- Diarrhea
- Flatulence
- Headache
- Joint pain
- Nausea
- Stomach pain
- Vomiting
- Dizziness
- Thrombophlebitis
How to use Panfirst 40mg Injection:
Administering this medication will be handled by your healthcare provider. Self-medication is strictly prohibited.
How Panfirst 40mg Injection works:
Acid reflux and indigestion find relief with Panfirst 40mg Injection, a proton pump inhibitor that diminishes stomach acid production.
SAFETY ADVICE
AlcoholUNSAFE
Consuming alcohol while using Panfirst 40mg Injection is inadvisable.
PregnancyCONSULT YOUR DOCTOR
The use of Panfirst 40mg Injection during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to the fetus. A physician will assess the advantages against possible risks prior to prescribing. Seek medical advice.
Breast feedingSAFE IF PRESCRIBED
Administration of Panfirst 40mg Injection during lactation appears to pose minimal risk. Available human data indicate negligible infant harm from the medication.
DrivingCONSULT YOUR DOCTOR
Driving ability while using Panfirst 40mg Injection is undetermined. Refrain from driving if experiencing symptoms impairing concentration or reaction time.
KidneySAFE IF PRESCRIBED
Panfirst 40mg Injection poses no safety concerns for patients with renal impairment; no dosage modification is necessary.
LiverCAUTION
For individuals with severe hepatic impairment, administration of Panfirst 40mg Injection requires careful consideration. Dosage modification of Panfirst 40mg Injection might be necessary. Physician consultation is advised.
What if you forget to take Panfirst 40mg Injection :
Omit a Panfirst 40mg Injection dose? Seek medical advice immediately.
Facts to Know About Panfirst 40mg Injection
| Label | Value |
|---|---|
| Chemical Classification | Benzimidazole Sulfoxide |
| Developing Habits | No. |
| Treatment Category | Gastrointestinal system |
| Actions | PPIs (proton pump inhibitors) |
